In the rapidly evolving landscape of oncology and immunotherapy, Anti-PD-1 Monoclonal Antibodies (MABs) have emerged as game-changers. These innovative drugs target the Programmed Death-1 (PD-1) protein on T-cells, effectively unleashing the immune system to attack cancer cells. Since the first approvals in the mid-2010s, Anti-PD-1 MABs have revolutionized treatment for various...